StockData

BillionToOne vs Burning Rock Biotech

BLLN and BNR side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BLLN and BNR compare

BillionToOne grew revenue faster over the last twelve months (71.9% versus 4.6% for Burning Rock Biotech).

BillionToOne keeps more of each dollar of sales as profit, with a net margin of 11.3% compared with −10.3% at Burning Rock Biotech.

BillionToOne scores higher on the StockData Score (11 against 4 for Burning Rock Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBLLNBNR
Size and price
Market cap$4.6B–
Share price$97.50$12.50
Change, 1 year8.3%6.5%
Change, 5 years–−90.9%
Beta (5Y)0.382.52
Employees713667
StockData Score
Total score11 (better)4
Valuation score00
Growth score3 (better)1
Performance score2 (better)1
Health score6 (better)2
Dividend score00
Valuation
P/S10.5×–
P/B8.1×–
EV/EBITDA77.8×–
P/FCF136×–
FCF yield0.74%–
Growth
Revenue growth (TTM)71.9% (better)4.6%
Revenue growth, 5Y average–4.6%
Profitability
Gross margin71.4%74.7% (better)
Operating margin10.2% (better)−10.2%
Net margin11.3% (better)−10.3%
FCF margin7.8% (better)−6.2%
Return on equity30.2% (better)−9.9%
Return on invested capital–−72.5%
Financial health
Debt / equity0.000.00 (better)
Interest coverage1655×–
Current ratio11.25 (better)2.99
Altman Z-score15.56–
Piotroski F-score8 (better)5
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions32.4%1.8%
Held by insiders55.7%19.0%
Insider net buying, 12 months−$58.5M$11.6M (better)
Short interest, % of float14.2%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.